跳至主要内容
临床试验/CTRI/2021/09/036474
CTRI/2021/09/036474Not Applicable2 期

“Clinical study for the evaluation of efficacy and safety of Unani formulation in the management of Cirrhosis of Liverâ€

Deptt of Moalajat School of Unani Medical Education and Research Jamia Hamdard University1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2021年9月20日最近更新:

试验速览

阶段
2 期
状态
Not Applicable
发起方
入组人数
30
试验地点
1
主要终点
A/G Ratio

研究概览

简要总结

The study entitled “Clinical study for the evaluation of efficacy and safety of Unani formulation in the management of Cirrhosis of Liver†is open label, single arm study will be carried out in department of Moalajat, Majeedia Unani Hospital, Jamia Hamdard, New Delhi. Diagnosed patients of cirrhosis of liver, who fit into the inclusion criteria, will be enrolled for the study. Test drugs which are selected for the study are safe and effective in liver diseases are mentioned in Unani literature. The test drugs will be prepared in the PG lab of department of Moalajat. Standardization and extraction of test drugs will be conducted in the department of Ilmul Advia, School of Unani Medical Education and Research, Jamia Hamdard. A written consent sheet will be provided to the patient in a language known to him/her before enrolment. Duration of the therapy will be three months with sample size of 30 patients and the follow up will be at baseline,15th ,30th,60th and 90th day. The Mizaj(temperament) of the patients will be assessed before treatment. The parameters for evaluation of efficacy and safety will be clinical sign and symptoms, MELD score, Child Pugh score, APRI score, biochemical parameters (CBC with ESR, LFT, KFT, B. Sugar, S. Electrolytes, S.GGT, HbA1C, HBsAg, AHCV, PT/INR and radiological parameters (USG and Fibroscan). The investigations will be done before the treatment, on 30th day and after completion of the treatment. At the end of the study the data thus generated will be statistically analyzed.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Not Applicable

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Radiological ( Elastography: Metavir score ≥ f4(i.e. more than 12kPa) evidence of liver cirrhosis Child-turcotte-Pugh Score A and B.

排除标准

  • Pregnant women and lactating mothers Mentally retarded patients Patients who failed to give informed consent Patient with Hepatic Encephalopathy Patients with comorbid heart and kidney disease History of active bleeding Severe bacterial infection History of malignancy Patient whose CHILD PUGH score lies in category C Uncontrolled Diabetes Mellitus.

结局指标

主要结局

A/G Ratio

时间窗: 0 Baseline, 15th day, 30th day, 60th day, 90th day

MELD Score

时间窗: 0 Baseline, 15th day, 30th day, 60th day, 90th day

APRI Score

时间窗: 0 Baseline, 15th day, 30th day, 60th day, 90th day

PT/INR,

时间窗: 0 Baseline, 15th day, 30th day, 60th day, 90th day

Hb level

时间窗: 0 Baseline, 15th day, 30th day, 60th day, 90th day

Child Pugh Score

时间窗: 0 Baseline, 15th day, 30th day, 60th day, 90th day

次要结局

  • Improvement in Quality of Life((SF12 Questionnaire))

研究者

发起方
Deptt of Moalajat School of Unani Medical Education and Research Jamia Hamdard University
申办方类型
Research institution and hospital

研究点 (1)

Loading locations...

相似试验